Anti-Mouse GITR Monoclonal Antibodies

Background of Anti-Mouse GITR Antibody

The rat anti-mouse GITR monoclonal antibody DTA-1 (rat IgG2b lambda) reacts with the mouse GITR protein (Glucocorticoid-Induced TNFR-Related protein or tumor necrosis factor receptor (TNFR) superfamily 18, TNFRSF 18). The DTA-1 monoclonal antibody reacts with the mouse GITR which is expressed predominantly by CD4+CD25+ T regulatory cells (Treg) and by CD25+ CD4+ CD8- thymocytes.

Our recombinant DTA-1 antibodies have a part (variable regions) or complete amino acid sequences of the rat anti-mouse GITR monoclonal antibody (hybridoma clone name or number: DTA-1).

PA007169.m2a: In Vivo Grade Recombinant Anti-Mouse GITR Mouse IgG2a Lambda Monoclonal Antibody

The in vivo grade recombinant anti-mouse GITR mouse IgG2a monoclonal antibody was produced in mammalian cells.
Specificity: GITR.
Clone: DTA-1.
Isotype: mouse IgG2a, lambda.
Applications: Western blot, immunoprecipitation (IP), Flow Cytometry (FC), and various in vitro and in vivo functional assays.
Formulation: 0.2 μM filtered solution of 1x PBS.
Purity: >95% by SDS-PAGE under reducing conditions.
Endotoxin Level: Less than 1 EU/mg of protein as determined by LAL method.

PA007169.r2b: In Vivo Grade Recombinant Anti-Mouse GITR Rat IgG2b Lambda Monoclonal Antibody

The in vivo grade recombinant anti-mouse GITR rat IgG2b monoclonal antibody was produced in mammalian cells.
Specificity: GITR.
Clone: DTA-1.
Isotype: rat IgG2b, lambda.
Applications: Western blot, immunoprecipitation (IP), Flow Cytometry (FC), and various in vitro and in vivo functional assays.
Formulation: 0.2 μM filtered solution of 1x PBS.
Purity: >95% by SDS-PAGE under reducing conditions.
Endotoxin Level: Less than 1 EU/mg of protein as determined by LAL method.

Shipping: The in vivo grade recombinant anti-mouse GITR antibodies (clone of DTA-1) are shipped with ice pack. Upon receipt, store it immediately at the temperature recommended below.
Stability & Storage: Use a manual defrost freezer and avoid repeated freeze-thaw cycles.
1 month from date of receipt, 2 to 8°C as supplied.
3 months from date of receipt, -20°C to -70°C as supplied.

In Vivo Grade Recombinant Anti-Mouse GITR Monoclonal Antibodies (Clone DTA-1):
In Vivo Grade Recombinant Anti-Mouse GITR Mouse IgG2a Monoclonal Antibody
In Vivo Grade Recombinant Anti-Mouse GITR Mouse IgG2a-LALAPG Monoclonal Antibody
In Vivo Grade Recombinant Anti-Mouse GITR Rat IgG2b Monoclonal Antibody
In Vivo Grade Recombinant Anti-Mouse GITR Mouse IgG1 Monoclonal Antibody
In Vivo Grade Recombinant Anti-Mouse GITR Mouse IgG1-D265A Monoclonal Antibody
In Vivo Grade Recombinant Anti-Mouse GITR Rabbit IgG Monoclonal Antibody

References of Anti-mouse GITR Monoclonal Antibody:

Influenza-Activated ILC1s Contribute to Antiviral Immunity Partially Influenced by Differential GITR Expression.
Vashist, N., et al. Front Immunol. 2018 Mar 22;9:505. doi: 10.3389/fimmu.2018.00505. PMID: 29623077
A novel association of ILC1 functionality and the expression of the glucocorticoid-induced TNFR-related protein (GITR) is observed, which hints toward a so far undescribed role of GITR in regulating ILC1 responsiveness. ... Overexpression of GITR inhibits IFN-? production by ILC1s, whereas partial reduction of GITR expression can reverse this effect, thereby regulating ILC1 functionality. ... The glucocorticoid-induced TNFR-related protein (GITR) is a receptor of the TNFR superfamily expressed on immune cell types such as regulatory T cells, naive T cells, and NK cells, as well as at lower levels on APCs. ... For in vivo targeting of GITR-GITR-L interactions, InvivoMAb anti mouse GITR (DTA-1, BioXCell, USA)/Isotype (LTF-2, BioXCell, USA), was used to stimulate GITR signaling (500 ?g/animal in 200 ?l PBS, i.p.). ... Wild-type mice were treated with either DTA-1 GITR agonist/isotype (500 ?g/animal) or GITR-Fc fusion chimera protein (6.25 ?g/animal) i.p.
Tags: anti-mouse GITR DTA-1; anti-mouse GITR DTA-1 mAb

Combined PD-1 blockade and GITR triggering induce a potent antitumor immunity in murine cancer models and synergizes with chemotherapeutic drugs.
Lu, L., et al. J Transl Med. 2014 Feb 7;12:36. doi: 10.1186/1479-5876-12-36. PMID: 24502656
Therapeutic anti-GITR (Clone DTA-1; Catalog#:BE0063), anti-PD-1 (Clone RMP1-14; Catalog#BE0146), anti-CD4 (Clone GK1.5; Catalog#:BE0003-1), anti-CD8 (Clone 2.43; Catalog#:BE0061), anti-NK1.1 (Clone PK136; Catalog#:BE0036) and control rat IgG (Clone 2A3; Catalog#:BE0089) monoclonal antibodies (mAb) were purchased from BioXcell (West Lebanon, NH). ... On days 8, 11 and 15, mice received the i.p. injection of 250 ?g of control, anti-PD-1, anti-GITR or anti-PD-1/GITR mAb in 250 ?L of PBS.... Although either single anti-PD-1 or anti-GITR mAb exhibited little antitumor effect, combined anti-PD-1/GITR mAb treatment significantly prolonged overall survival time of mice (Figure 1B; median survival time 31.50, 34.00, 33.00 or >75.00 days for control, anti-PD-1, anti-GITR or anti-PD-1/GITR mAb group respectively; p < 0.01, combined mAb compared to single or control mAb) with 20% (2 out of 10 mice) of mice remaining tumor-free (confirmed by laparotomy) 90 days after tumor challenge (Figure 1C). ... Cell depleting experiments showed that tumor protection was dependent on the CD4+ and CD8+ T cells as removal of CD4+ or CD8+ T cells abrogated the antitumor effect conferred by anti-PD-1/GITR mAb treatment (Figure 1F). ... Compared with control or single mAb, combined mAb significantly increased the percentages of effector CD4+FoxP3- T cells (mean value 7.70%, 7.78%, 11.94% and 31.50% for control, anti-PD-1, anti-GITR and anti-PD-1/GITR group respectively; p < 0.01) and CD8+ T cells (mean value 11.34%, 12.62%, 17.96% and 41.04%; p < 0.05) and decreased the frequency of CD4+FoxP3+ regulatory T cells (Treg; mean value 9.72%, 10.44%, 6.44% and 2.54%; p < 0.05 and p < 0.01 compared to anti-GITR and control or anti-PD-1 respectively) and CD11b+GR-1+ myeloid-derived suppressor cells (MDSC; mean value 24.58%, 22.28%, 19.18% and 8.04%; p < 0.05 and p < 0.01 compared to anti-GITR or anti-PD-1 and control respectively) in TAC on day 7 after treatment (Figure 2A-D); These contrasting changes in effector and immunosuppressive cells gave rise to the significantly elevated ratios of both effector CD4+ and CD8+ T cells to Treg and MDSC in peritoneal cavity of mice receiving combined mAb treatment (Figure 2E-H).
Tags: anti-mouse GITR DTA-1 antibody in vivo; anti-mouse GITR DTA-1 in animal model

Activating Fc ? receptors contribute to the antitumor activities of immunoregulatory receptor-targeting antibodies.
Bulliard, Y., et al. J Exp Med. 2013 Aug 26;210(9):1685-93. doi: 10.1084/jem.20130573. PMID: 23897982
To evaluate the contribution of activating or inhibitory Fc?Rs in the mechanism of tumoricidal activity of an agonist antibody targeting GITR (clone DTA-1, rat IgG2b), Colon26 colorectal cancer cells were implanted subcutaneously in wild-type, Fc?RIIB-, or Fc common ? chain?deficient mice. ... As previously shown for this tumor model, DTA-1?mediated single dose regressions in 100% of wild-type mice. ... To further examine the contribution of activating Fc?Rs for the tumoricidal activity of antibodies to GITR, we generated two chimeric antibodies from the parental DTA-1 rat IgG2b: a murine IgG2a (mIgG2a), and mIgG2a with a N297A mutation that eliminates binding to all murine Fc?Rs. ... Both DTA-1 rIgG2b and mIgG2a showed potent antitumor efficacy, which was abrogated in absence of activating Fc?Rs but was not impacted by the absence of Fc?RIIB expression. ... Eliminating Fc?R interaction through the N297A mutation abrogated the antitumor activity of DTA-1.
Tags: anti-mouse GITR DTA-1 mAb in animal model; anti-mouse GITR DTA-1 in cancer research

Regulatory T cell suppressive potency dictates the balance between bacterial proliferation and clearance during persistent Salmonella infection.
Johanns, T. M., et al. PLoS Pathog. 2010 Aug 12;6(8):e1001043. doi: 10.1371/journal.ppat.1001043. PMID: 20714351
For example, molecules that have independently been associated with diminished Treg suppression potency such as reduced CTLA-4 and increased GITR expression were found for Foxp3 + Tregs from mice day 5 compared with day 37 after infection. ...hus, reduction in Treg suppressive potency during the progression of persistent Salmonella infection directly parallels reduced CTLA-4 and increased GITR expression that each independently correlates with this shift in suppression. ...The relative expression of CTLA-4 and GITR on Foxp3+ Tregs (line histogram) or Foxp3-negative CD4+ T cells (shaded histogram) at the indicated time points during persistent infection. ...FliC431?439-specific Tregs were found to down-regulate CTLA-4 and up-regulate GITR expression, as infection progressed from early to late time points to a similar extent in FliC431?439-specific compared with bulk Tregs at these same time points after infection. ...To more definitively identify the relative importance of Treg-mediated immune suppression on the progression of persistent Salmonella infection, the impacts of Treg ablation on infection tempo and T cell activation were enumerated at early and late time points after infection.
Tags: anti-mouse GITR DTA-1 mAb in cancer research; anti-mouse GITR DTA-1 mAb in mouse tumor model

For more references about Anti-mouse GITR Monoclonal Antibody please contact our scientific support team with message@sydlabs.com.